Pharmacology and Co-occurring Disorders
What this domain tests
Pharmacology and Co-occurring Disorders tests whether you understand medication-assisted treatment, psychiatric medications, withdrawal, drug interactions, overdose risk, and integrated care. You are not prescribing, but you must recognize indications, common effects, safety concerns, and myths that affect adherence.
Core rules
- Medication for opioid use disorder includes methadone, buprenorphine, and naltrexone. These are evidence-based treatments, not substitutes for counseling or evidence of continued use. Do not tell clients to stop effective medication without prescriber involvement.
- Alcohol use disorder medications include naltrexone, acamprosate, and disulfiram. Disulfiram requires abstinence, informed consent, and medical clearance because it can cause a severe reaction with alcohol and is risky in liver disease.
- Opioid and benzodiazepine co-use raises overdose risk. Stimulant toxicity and alcohol withdrawal can become medical emergencies.
- Psychiatric medications have interactions and adverse effects. Refer medication questions to the prescriber; do not adjust or advise stopping.
- Integrated treatment addresses substance use and co-occurring mental health conditions together. Do not require one condition to be treated first as a precondition for the other.
- Medication adherence is a clinical issue, not a character issue. Explore barriers, side effects, stigma, cost, and misinformation.
Worked example
A client with alcohol use disorder asks about disulfiram after a relapse. The client still drinks several times weekly and has cirrhosis. The counselor should not endorse disulfiram as a quick fix. The reasoning: disulfiram needs abstinence and medical clearance, and severe liver disease is a contraindication. The counselor refers to the prescriber to discuss alternatives such as naltrexone or acamprosate and continues counseling and safety planning. The counselor documents the request, the referral, and the client's understanding.
Traps that cost marks
- Telling a client that buprenorphine or methadone is just trading one drug for another.
- Discussing disulfiram without abstinence, consent, or medical review.
- Ignoring opioid and benzodiazepine co-use.
- Advising a client to stop psychiatric medication.
- Assuming medication alone is sufficient treatment.
- Requiring abstinence from all substances before mental health treatment.